国际外科学杂志
國際外科學雜誌
국제외과학잡지
INTERNATIONAL JOURNAL OF SURGERY
2014年
5期
333-337,封3
,共6页
胰腺肿瘤%血浆%循环microRNA%吉西他滨%耐药%微RNAs
胰腺腫瘤%血漿%循環microRNA%吉西他濱%耐藥%微RNAs
이선종류%혈장%순배microRNA%길서타빈%내약%미RNAs
Pancreatic neoplasms%Plasma%Circulating microRNA%Gemcitabine%Drug resistance%MicroRNAs
目的 检测胰腺癌患者血浆中表达差异的microRNA及对吉西他滨耐药的胰腺癌患者血浆中表达差异的microRNA,为寻找新的生物标志物用于胰腺癌的无创性诊断及吉西他滨的疗效预测提供新的思路.方法 采用qPCR方法检测并筛选出胰腺癌患者血浆中相比于健康人表达差异明显的microRNA,以及对吉西他滨耐药的胰腺癌患者血浆中相比于对吉西他滨不耐药的胰腺癌患者表达差异明显的microR-NA.结果 胰腺癌患者相较于健康人存在表达差异的microRNA有28个,对吉西他滨耐药的胰腺癌患者相较于不耐药患者存在表达差异的microRNA有28个.结论 胰腺癌患者血浆中microRNA表达与正常人群有较显著的差异,胰腺癌患者中对吉西他滨耐药和不耐药者血浆microRNA也存在较显著差异,其有可能作为胰腺癌的诊断及疗效预测提供潜在的生物标志物.
目的 檢測胰腺癌患者血漿中錶達差異的microRNA及對吉西他濱耐藥的胰腺癌患者血漿中錶達差異的microRNA,為尋找新的生物標誌物用于胰腺癌的無創性診斷及吉西他濱的療效預測提供新的思路.方法 採用qPCR方法檢測併篩選齣胰腺癌患者血漿中相比于健康人錶達差異明顯的microRNA,以及對吉西他濱耐藥的胰腺癌患者血漿中相比于對吉西他濱不耐藥的胰腺癌患者錶達差異明顯的microR-NA.結果 胰腺癌患者相較于健康人存在錶達差異的microRNA有28箇,對吉西他濱耐藥的胰腺癌患者相較于不耐藥患者存在錶達差異的microRNA有28箇.結論 胰腺癌患者血漿中microRNA錶達與正常人群有較顯著的差異,胰腺癌患者中對吉西他濱耐藥和不耐藥者血漿microRNA也存在較顯著差異,其有可能作為胰腺癌的診斷及療效預測提供潛在的生物標誌物.
목적 검측이선암환자혈장중표체차이적microRNA급대길서타빈내약적이선암환자혈장중표체차이적microRNA,위심조신적생물표지물용우이선암적무창성진단급길서타빈적료효예측제공신적사로.방법 채용qPCR방법검측병사선출이선암환자혈장중상비우건강인표체차이명현적microRNA,이급대길서타빈내약적이선암환자혈장중상비우대길서타빈불내약적이선암환자표체차이명현적microR-NA.결과 이선암환자상교우건강인존재표체차이적microRNA유28개,대길서타빈내약적이선암환자상교우불내약환자존재표체차이적microRNA유28개.결론 이선암환자혈장중microRNA표체여정상인군유교현저적차이,이선암환자중대길서타빈내약화불내약자혈장microRNA야존재교현저차이,기유가능작위이선암적진단급료효예측제공잠재적생물표지물.
Objective To investigate the differentially expressed circulating microRNAs of pancreatic cancer,and of the pancreatic cancer with gemcitabine resistance,to find potential biomarkers for noninvasive diagnosis of pancreatic cancer and the prediction of prognosis of gemcitabine.Methods To screen the highly deregulated microRNAs in the plasma samples of pancreatic cancer,and in the plasma samples ofpancreatic cancer patients with gemcitabine resistance using reverse transcription and quantitative PCR.Results Twenty-eight microRNAs expressing differentially with fold-exchange ＞ 2 was screened out comparing pancreatic cancer and healthy controls,and 28 microRNAs was screened out comparing gemcitabine resistant patients and gemcitabine positive patients.Conclusions There is a specific circulating mIcroRNA profile in pancreatic cancer as well as in pancreatic cancer with gemcitabine resistance.These profiles may have potential in noninvasive diagnosis of pancreatic cancer and the prediction of prognosis of gemcitabine.
